HMO Infant Formula Synergy with LCPUFAs for Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current infant formulas lack effective means to modulate inflammation and enhance immunity against microbial infections, particularly in preterm and term infants, due to the immaturity of their immune systems and the absence of vaccines for inflammatory diseases.
Innovation Solution
Development of synthetic infant, pediatric, and child formulas containing human milk oligosaccharides (HMOs) combined with long chain polyunsaturated fatty acids (LCPUFAs), antioxidants, and nucleotides to reduce inflammation and enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If synthetic infant formulas are used instead of breast milk, then nutritional supplementation is provided, but inflammation modulation and immune enhancement capabilities are lost
Solution Approach 1:
The patent introduces human milk oligosaccharides (HMOs) as intermediary substances in synthetic formulas to mediate immune modulation and inflammation reduction. HMOs act as functional additives that bridge the gap between nutritional supplementation and immune support, enabling synthetic formulas to achieve some of breast milk's protective effects without requiring actual breast milk consumption.
Solution Approach 2:
The patent creates composite nutritional formulations by combining synthetic base ingredients with HMOs, LCPUFAs, antioxidants, and nucleotides. This composite approach allows the formula to integrate multiple functional components that work synergistically to provide both nutritional value and immune modulation, resolving the contradiction between synthetic composition and biological functionality.
2Reliability
If HMOs are added to synthetic formulas at high concentrations, then anti-inflammatory effects are enhanced, but formulation complexity and cost increase
Solution Approach 1:
The patent identifies and optimizes specific concentration parameters for HMOs and other functional ingredients to achieve effective anti-inflammatory results. By determining the minimum effective concentrations rather than using high concentrations universally, the formulation maintains effectiveness while reducing complexity and cost. The patent specifies particular amounts of HMOs, LCPUFAs, and antioxidants that provide synergistic benefits without excessive formulation complexity.
3Reliability
If multiple functional components (HMOs, LCPUFAs, antioxidants, nucleotides) are combined in formulas, then immune function is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent merges multiple functional components—HMOs, LCPUFAs, antioxidants, and nucleotides—into unified formula compositions where they work synergistically to enhance immune function. By combining these ingredients in specific ratios and matrices, the patent achieves enhanced immune support while managing manufacturing complexity through integrated formulation approaches rather than separate additive processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HMOs, such as 3′-sialyllactose and 6′-sialyllactose, demonstrate significant anti-inflammatory effects by reducing cytokine production and viral-induced inflammation, even at low concentrations, providing a synergistic benefit when combined with LCPUFAs and antioxidants, thereby improving immune function and reducing oxidative stress.
Implementation Method 1
HMOs that not only act as pathogen receptor analogues, but activate immune factors by infant intestinal epithelial cells and/or associated immune cell populations
Implementation Method 2
HMOs, such as 3′-sialyllactose and 6′-sialyllactose, demonstrate significant anti-inflammatory effects by reducing cytokine production and viral-induced inflammation
Implementation Method 3
Breast milk appears to contain endogenous antioxidants, such as superoxide dismutase, glutathione peroxidase and catalase, or other non-enzymatic antioxidants such as glutathione, lactoferrin and polyphenols
Implementation Method 4
The function of these breast milk components, functioning as antioxidants and as immune modulators, includes not only the protection of breast milk lipids by peroxidation
Implementation Method 5
providing a synergistic benefit when combined with LCPUFAs and antioxidants, thereby improving immune function and reducing oxidative stress
Data Source
AI summary
Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.